Indeed, in these short-term experiments, daratumumab predominantly kills tumor cells via direct on-tumor mechanisms of action (ADCC and ADCP), which require the presence of CD38 on the tumor cell surface and Fc-receptor-bearing immune effector cells (i.e., NK-cells and macrophages) in the BM microenvironment [10,11]. Here, CD38 is linked to neoplasm.